How Shapeshifting Tumor Cells Outsmart Cancer Treatment
A new review explains how tumor cells reversibly switch identities through epigenetic and microenvironmental programs, driving metastasis and therapy resistance.
A new review explains how tumor cells reversibly switch identities through epigenetic and microenvironmental programs, driving metastasis and therapy resistance.
A new review in the Journal of Neuro-Oncology outlines how patient-derived tumor platforms such as organoids and organ-on-chip systems, combined ...
New research shows that the mitochondrial enzyme GDH1 sustains drug-tolerant persister cells in triple-negative breast cancer by coordinating glutamine metabolism, ...
Researchers have discovered that the calcium-rich bone microenvironment drives chemotherapy tolerance in osteosarcoma through an ORAI3–Ca²⁺–NFAT4–PINK1 mitophagy axis that can ...
A new Molecular Cancer study reveals how UQCRC2 lactylation and SIRT1-driven mitophagy allow colorectal cancer cells to survive chemotherapy in ...
Six emerging cancer researchers outline in a Nature Reviews Cancer anniversary viewpoint the technologies and paradigms that will shape oncology ...
In the relentless battle against cancer, the phenomenon of drug-tolerant persister (DTP) cells continues to pose a substantial challenge, complicating ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine